Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Sneha Berry¹, Nicolas Giraldo², Peter Nguyen², Benjamin Green², Haiying Xu², Aleksandra Ogurtsova², Abha Soni², Farah Succaria², Daphne Wang², Charles Roberts², Julie Stein², Elizabeth Engle², Drew Pardoll², Robert Anders², Tricia Cottrell², Janis M Taube², Ben Tran³, Mark Voskoboynik⁴, James Kuo⁵, Yung-Lue Bang⁶, Hyun-Cheo Chung⁷, Myung-Ju Ahn⁸, Sang-We Kim⁹, Ayesh Perera¹⁰, Daniel Freeman¹⁰, Ikbel Achour¹⁰, Raffaella Faggioni¹⁰, Feng Xiao¹⁰, Charles Ferte¹¹, Charlotte Lemech⁵, Funda Meric-Bernstam¹², Theresa Werner¹³, Stephen Hodi¹⁴, Wells Messersmith¹⁵, Nancy Lewis¹⁶, Craig Talluto¹⁷, Mirek Dostalek¹⁶, Aiyang Tao¹⁶, Sarah McWhirter¹⁸, Damian Trujillo¹⁸, Jason Luke¹⁹, Chunxiao Xu²⁰, BoMarelli²⁰, Jin Qi²⁰, Guozhong Qin²⁰, Huakui Yu²⁰, Molly Jenkins²⁰, Kin-Ming Lo²⁰, Joern-Peter Halle²⁰, Yan Lan²¹, Matthew Taylor²², Nicholas Vogelzang²³, Allen Cohn²³, Daniel Stepan²⁴, Robert Shumaker²⁴, Corina Dutcus²⁴, Matthew Guo²⁴, Emmett Schmidt²⁵, Drew Rasco²⁶, Marcia Brose²⁷, Nicholas Vogelzang²³, Christopher Di Simone²³, Sharad Jain²³, Donald Richards²³, Carlos Encarnacion²³, Drew Rasco²⁶, Robert Shumaker²⁴, Corina Dutcus²⁴, Daniel Stepan²⁴, Matthew Guo²⁴, Emmett Schmidt²⁵, Matthew Taylor²⁸, Nicholas Vogelzang²⁹, Carlos Encarnacion²³, Allen Cohn²³, Christopher Di Simone²³, Drew Rasco²⁶, Donald Richards²³, Matthew Taylor²⁸, Corina Dutcus²⁴, Daniel Stepan²⁴, Robert Shumaker²⁴, Matthew Guo²⁴, Emmett Schmidt²⁵, James Mier³⁰, Jeongshin An³¹, Yeun-Yeoul Yang³², Won-Hee Lee³³, Jinho Yang³³, Jong-Kyu Kim³², Hyun Goo Kim³², Se Hyun Paek³², Jun Woo Lee³², Joohyun Woo³², Jong Bin Kim³², Hyungju Kwon³², Woosung Lim³², Nam Sun Paik³², Yoon-Keun Kim³³, Byung-In Moon³², Filip Janku³⁴, David Tan³⁵, Juan Martin-Liberal³⁶, Shunji Takahashi³⁷, Ravit Geva³⁸, Ayca Gucalp³⁹, Xueying Chen¹⁶, Kulandayan Subramanian¹⁷, Jennifer Mataraza¹⁷, Jennifer Wheler¹⁷, Philippe Bedard⁴⁰

Affiliations

¹ Johns Hopkins University School of Medicine, Baltimore, MD, USA. jtaube1@jhmi.edu.
² Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Peter MacCallum Cancer Center, Melbourne, Australia.
⁴ Nucleus Network, Melbourne, Australia.
⁵ Scientia Clinical Research, Sydney, Australia.
⁶ Seoul National University Hospital, Seoul, Korea, Republic of.
⁷ Yonsei Cancer Center, Yonsei University, Seoul, Korea, Republic of.
⁸ Samsung Medical Center, Seoul, Korea, Republic of.
⁹ Asan Medical Center, Songpa-Gu, Korea, Republic of.
¹⁰ MedImmune, Gaithersburg, MD, USA.
¹¹ MedImmune, Gaithersburg, MD, USA. fertec@MedImmune.com.
¹² MD Anderson Cancer Center, Houston, TX, USA. fmeric@mdanderson.org.
¹³ University of Utah, Salt Lake City, UT, USA.
¹⁴ Dana-Faber Cancer Institute, Boston, MA, USA.
¹⁵ University of Colorado Cancer Center, Aurora, CO, USA.
¹⁶ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
¹⁷ Novartis Institutes for BioMedical Resea, Cambridge, MA, USA.
¹⁸ Aduro Biotech Inc, Berkeley, CA, USA.
¹⁹ The University of Chicago Medicine, Chicago, IL, USA.
²⁰ EMD Serono Research and Development, Belmont, MA, USA.
²¹ EMD Serono Research and Development, Belmont, MA, USA. yan.lan@emdserono.com.
²² Oregon Health and Science University, Portland, OR, USA. taylmatt@ohsu.edu.
²³ McKesson Specialty Health, Las Vegas, NV, USA.
²⁴ Eisai Inc., Woodcliff Lake, NJ, USA.
²⁵ Merck & Co., Inc., Kenilworth, NJ, USA.
²⁶ South Texas Accelerated Research Therape, San Antonio, TX, USA.
²⁷ Abramson Cancer Center of the University, Philadelphia, PA, USA. Brosem@mail.med.upenn.edu.
²⁸ Oregon Health and Science University, Portland, OR, USA.
²⁹ McKesson Specialty Health, Las Vegas, NV, USA. nicholas.vogelzang@usoncology.com.
³⁰ Beth Israel Deaconess Medical Center, Boston, MA, USA.
³¹ Ewha Womans University, Seoul, Korea, Republic of. rulru81@hanmail.net.
³² Ewha Womans University, Seoul, Korea, Republic of.
³³ MD healthcare company, Seoul, Korea, Republic of.
³⁴ MD Anderson Cancer Center, Houston, TX, USA. fjanku@mdanderson.org.
³⁵ National University Cancer Institute, Singapore, Singapore.
³⁶ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
³⁷ The Cancer Institute Hospital of JFCR, Tokyo, Japan.
³⁸ Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
³⁹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴⁰ Princess Margaret Cancer Centre, Toronto, ON, Canada.

PMID: 30760319
PMCID: PMC6373015
DOI: 10.1186/s40425-019-0519-y

Published Erratum

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Sneha Berry et al. J Immunother Cancer. 2019.

. 2019 Feb 13;7(1):46.

doi: 10.1186/s40425-019-0519-y.

Authors

Affiliations

¹ Johns Hopkins University School of Medicine, Baltimore, MD, USA. jtaube1@jhmi.edu.
² Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Peter MacCallum Cancer Center, Melbourne, Australia.
⁴ Nucleus Network, Melbourne, Australia.
⁵ Scientia Clinical Research, Sydney, Australia.
⁶ Seoul National University Hospital, Seoul, Korea, Republic of.
⁷ Yonsei Cancer Center, Yonsei University, Seoul, Korea, Republic of.
⁸ Samsung Medical Center, Seoul, Korea, Republic of.
⁹ Asan Medical Center, Songpa-Gu, Korea, Republic of.
¹⁰ MedImmune, Gaithersburg, MD, USA.
¹¹ MedImmune, Gaithersburg, MD, USA. fertec@MedImmune.com.
¹² MD Anderson Cancer Center, Houston, TX, USA. fmeric@mdanderson.org.
¹³ University of Utah, Salt Lake City, UT, USA.
¹⁴ Dana-Faber Cancer Institute, Boston, MA, USA.
¹⁵ University of Colorado Cancer Center, Aurora, CO, USA.
¹⁶ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
¹⁷ Novartis Institutes for BioMedical Resea, Cambridge, MA, USA.
¹⁸ Aduro Biotech Inc, Berkeley, CA, USA.
¹⁹ The University of Chicago Medicine, Chicago, IL, USA.
²⁰ EMD Serono Research and Development, Belmont, MA, USA.
²¹ EMD Serono Research and Development, Belmont, MA, USA. yan.lan@emdserono.com.
²² Oregon Health and Science University, Portland, OR, USA. taylmatt@ohsu.edu.
²³ McKesson Specialty Health, Las Vegas, NV, USA.
²⁴ Eisai Inc., Woodcliff Lake, NJ, USA.
²⁵ Merck & Co., Inc., Kenilworth, NJ, USA.
²⁶ South Texas Accelerated Research Therape, San Antonio, TX, USA.
²⁷ Abramson Cancer Center of the University, Philadelphia, PA, USA. Brosem@mail.med.upenn.edu.
²⁸ Oregon Health and Science University, Portland, OR, USA.
²⁹ McKesson Specialty Health, Las Vegas, NV, USA. nicholas.vogelzang@usoncology.com.
³⁰ Beth Israel Deaconess Medical Center, Boston, MA, USA.
³¹ Ewha Womans University, Seoul, Korea, Republic of. rulru81@hanmail.net.
³² Ewha Womans University, Seoul, Korea, Republic of.
³³ MD healthcare company, Seoul, Korea, Republic of.
³⁴ MD Anderson Cancer Center, Houston, TX, USA. fjanku@mdanderson.org.
³⁵ National University Cancer Institute, Singapore, Singapore.
³⁶ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
³⁷ The Cancer Institute Hospital of JFCR, Tokyo, Japan.
³⁸ Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
³⁹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴⁰ Princess Margaret Cancer Centre, Toronto, ON, Canada.

PMID: 30760319
PMCID: PMC6373015
DOI: 10.1186/s40425-019-0519-y

Abstract

After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

PubMed Disclaimer

Conflict of interest statement

This study was approved by an independent ethics committee or institutional review board at each site.

Erratum for

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.
[No authors listed] [No authors listed] J Immunother Cancer. 2018 Nov 6;6(Suppl 1):115. doi: 10.1186/s40425-018-0423-x. J Immunother Cancer. 2018. PMID: 30400822 Free PMC article. No abstract available.
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.
[No authors listed] [No authors listed] J Immunother Cancer. 2018 Nov 6;6(Suppl 1):114. doi: 10.1186/s40425-018-0422-y. J Immunother Cancer. 2018. PMID: 30400835 Free PMC article. No abstract available.

References

1. Benhaddi, et al. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immuno Therapy Cancer. 2018;6(Suppl 1) 10.1186/s40425-018-0422-y.
1. Benhaddi, et al. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immuno Therapy Cancer. 2018;6(Suppl 1) 10.1186/s40425-018-0423-x.

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Affiliations

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Authors

Affiliations

Abstract

Conflict of interest statement

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources